Latest news with #USPH
Business Wire
12-06-2025
- Business
- Business Wire
U.S. Physical Therapy Presented at Investor Conferences
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chief Executive Officer, presented at the Goldman Sachs 46 th Annual Global Healthcare Conference on June 10, 2025, and Carey Hendrickson, Chief Financial Officer, presented at the 15th Annual East Coast IDEAS Conference on June 11, 2025. The presentations provided an overview of the Company. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 775 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release.
Yahoo
11-06-2025
- Business
- Yahoo
USPH Q1 Earnings Call: Management Highlights Volume Growth and Contracting Initiatives Amid Medicare Headwinds
Outpatient physical therapy provider U.S. Physical Therapy (NYSE:USPH) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 18.1% year on year to $183.8 million. Its non-GAAP profit of $0.48 per share was 6.2% above analysts' consensus estimates. Is now the time to buy USPH? Find out in our full research report (it's free). Revenue: $183.8 million vs analyst estimates of $176.1 million (18.1% year-on-year growth, 4.4% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (6.2% beat) Adjusted EBITDA: $19.54 million vs analyst estimates of $18.44 million (10.6% margin, 5.9% beat) Operating Margin: 10.7%, up from 9.2% in the same quarter last year Sales Volumes rose 13.9% year on year (3.3% in the same quarter last year) Market Capitalization: $1.2 billion U.S. Physical Therapy's management attributed first quarter performance to a combination of higher patient volumes, ongoing efforts to negotiate improved commercial and workers' compensation rates, and contributions from recent acquisitions such as Metro Physical Therapy. CEO Chris Reading noted that, despite challenging weather early in the quarter, March finished with a record number of visits per clinic per day, helping offset earlier disruptions. The injury prevention division also delivered notable organic and acquired growth, with revenue and profit both rising sharply year over year. CFO Carey Hendrickson emphasized the impact of increased rates and successful payer contracting, particularly within workers' compensation, as important contributors to overall revenue growth. Looking ahead, management identified several themes likely to shape future results. Chris Reading cited ongoing rate negotiations with commercial payers and continued expansion of the home care offering, especially through leveraging Metro's expertise, as areas of focus. The company expects further growth in injury prevention services, both organically and through new contracts, and is monitoring legislative developments around Medicare reimbursement rates. While Reading acknowledged that staffing remains tight and macroeconomic uncertainty could create challenges, he stated, 'We have a playbook for navigating downturns and are seeing strong demand across our markets.' The company aims to provide updated guidance after monitoring trends in the coming months. Management attributed the quarter's results to robust demand, successful rate negotiations, and the integration of recent acquisitions, but also pointed to ongoing headwinds from Medicare rate reductions and staffing pressures. Volume recovery post-weather disruptions: Patient volumes rebounded strongly after weather-related closures in January and February, with March setting a new high for visits per clinic per day. This recovery was especially pronounced in long-standing markets and at Metro, the November acquisition, which saw visits per clinic per day grow from 44 to about 50 by March. Acquisitions and home care expansion: The Metro acquisition contributed significantly to revenue, and management is leveraging Metro's experience as it begins to introduce home-based care to additional markets. Metro's model, which includes physical, occupational, and speech therapy plus home care, is being introduced to other partnerships, with plans for broader reach. Injury prevention services momentum: The industrial injury prevention (IIP) segment posted strong organic and acquired growth, with revenue and profit up nearly 29% year over year. Management noted both new client wins and contract expansions as drivers, and sees this segment as a 'greenfield' opportunity given low market penetration. Rate improvements despite Medicare cuts: The company achieved a net rate per visit increase of over $2 compared to last year, overcoming a 2.9% Medicare rate reduction. Workers' compensation rates rose by about 10%, and strategic payer negotiations, particularly with large insurers like Blue Cross Blue Shield, are expected to provide ongoing support. Cost management and margin focus: Despite higher average salary and operating costs due to acquisitions, management is closely monitoring productivity, cost per visit, and partner-level performance. Direct involvement with top partnerships and targeted support initiatives are aimed at improving operating margins throughout the year. Management's outlook centers on contract negotiations, expansion of home care and injury prevention, and ongoing cost controls, while monitoring headwinds from reimbursement rates and staffing. Payer contracting and rate negotiations: The company's strategic focus on renegotiating commercial and workers' compensation contracts is expected to drive rate improvements. Recent progress with large insurers, particularly in markets like Texas and New York, should support revenue growth and help offset potential future government reimbursement cuts. Expansion of home care and ancillary services: Management is actively introducing home care offerings, leveraging Metro's established model, and exploring the expansion of cash-based services like laser therapy with select partnerships. This diversification aims to serve previously unaddressed patient segments—especially those unable to access clinics—and create additional revenue streams. Injury prevention segment growth: The industrial injury prevention business continues to secure new contracts, including with government clients, and is working to deepen relationships with existing employer partners. Management views this as an underpenetrated market with opportunities for both organic expansion and selective acquisitions, though acknowledges some contracts may carry lower margins. In the coming quarters, the StockStory team will closely watch (1) the pace and profitability of new home care and injury prevention contract wins, (2) the progression of commercial and workers' compensation rate negotiations, and (3) the impact of ongoing cost management efforts on operating margins. We will also monitor legislative developments that could affect Medicare reimbursement and the ability to scale ancillary services across more partnerships. U.S. Physical Therapy currently trades at a forward P/E ratio of 29.3×. In the wake of earnings, is it a buy or sell? The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
U.S. Physical Therapy Announces Dual Listing on NYSE Texas
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (the 'Company') (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services headquartered in Houston, Texas, today announced a dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange based in Dallas, Texas. U.S. Physical Therapy will maintain its primary listing on the New York Stock Exchange and trade with the same 'USPH' ticker symbol on NYSE Texas. Chris Reading, Chairman and Chief Executive Officer, said, 'We are honored to join NYSE Texas as a Founding Member and to champion the dynamic growth, energy and grit that define this great state. Being based in Texas has been a key advantage for us – helping us attract top talent and playing a significant role in our growth and success across the nation. Texas' strong and diverse economy makes it an exceptional place to do business.' 'As the first healthcare company to list on NYSE Texas, we are proud to welcome Chris and the USPH team to our growing community of Founding Members,' said Chris Taylor, Chief Development Officer, NYSE Group. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 776 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release.
Yahoo
09-05-2025
- Business
- Yahoo
US Physical Therapy Inc (USPH) Q1 2025 Earnings Call Highlights: Record Demand and Strategic ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. US Physical Therapy Inc (NYSE:USPH) reported a record high average visits per day for any first quarter in its history, indicating strong demand. The company's injury prevention segment saw a significant revenue increase of 29% year-over-year, showcasing robust growth. USPH's strategic focus on increasing reimbursement rates through contract negotiations has resulted in a net rate increase despite Medicare rate cuts. The acquisition of Metro, USPH's largest acquisition, has shown promising results with high visits per clinic per day and strong leadership. USPH's balance sheet remains strong with a favorable term loan rate and a well-positioned capital structure for future acquisitions. USPH faced significant weather-related disruptions in the first quarter, resulting in the loss of approximately 26,000 visits. The company's physical therapy margin decreased from 17.9% in the first quarter of last year to 16.3% this year, partly due to acquisitions with lower margins. There is ongoing pressure from Medicare rate cuts, which have accumulated to a significant profit impact over the years. USPH's mature clinic revenue was down year-over-year, impacted by weather and calendar effects. The company is cautious about updating guidance due to uncertainties and prefers to wait for more data before making adjustments. Warning! GuruFocus has detected 7 Warning Signs with USPH. Q: Can you explain the impact of weather on mature clinic revenue and how it affected the overall volume? A: Chris Redding, Chairman and CEO, explained that the weather had a significant impact, particularly in large partner markets like Nashville and Texas, where clinics were closed for multiple days due to extreme weather conditions. Despite this, demand remains high, and they expect a rebound in volume as indicated by strong performance in March. Q: How has US Physical Therapy historically managed economic downturns, and what is the current outlook? A: Chris Redding noted that during the 2008-2009 recession, the company made strategic adjustments and continued to grow. They have a playbook from that period and are prepared to implement similar strategies if necessary. Current demand is strong, and they are optimistic about managing any potential downturn. Q: What are the growth drivers for the Industrial Injury Prevention (IIP) segment, and what is the potential for expansion? A: Chris Redding highlighted that the IIP segment is driven by successful injury prevention programs that reduce reported injuries and insurance claims for clients. The segment has significant greenfield opportunities, and while there are fewer acquisition targets, the organic growth potential is substantial. Q: Can you provide more details on the home care opportunity and its attractiveness? A: Chris Redding explained that home care is attractive due to patient demand for convenient care and the ability to serve patients who are temporarily homebound. It offers flexibility for clinicians and is profitable due to higher reimbursement rates in certain markets like New York. Q: What progress has been made in renegotiating rates for Metro, and what impact has this had? A: Kerrie Hendrickson, CFO, stated that Metro has seen rate improvements, with a significant contract taking effect in May. The rate for Metro increased from $102.40 to $104.50 per visit in the first quarter, with further improvements expected as more contracts are renegotiated. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
08-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and Barinthus Biotherapeutics (BRNS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on US Physical Therapy (USPH – Research Report) and Barinthus Biotherapeutics (BRNS – Research Report). Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. US Physical Therapy (USPH) In a report released today, Ryan Daniels from William Blair reiterated a Hold rating on US Physical Therapy. The company's shares closed last Wednesday at $70.96. According to Daniels is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Lifestance Health Group, and Pediatrix Medical Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for US Physical Therapy with a $108.25 average price target. Barinthus Biotherapeutics (BRNS) In a report released today, Andy Hsieh from William Blair reiterated a Buy rating on Barinthus Biotherapeutics. The company's shares closed last Wednesday at $0.99, close to its 52-week low of $0.80. According to Hsieh is a 4-star analyst with an average return of 6.0% and a 43.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Corbus Pharmaceuticals, and Terns Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Barinthus Biotherapeutics with a $4.50 average price target.
